Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
Recursion Pharmaceuticals
Combines automation and machine learning to industrialize drug discovery and development.
What they do
Recursion Pharmaceuticals uses automated biology, high throughput imaging, and machine learning to decode human cellular biology. The company licenses their discovery platform and drug pipeline to global biopharma companies looking to accelerate therapeutic breakthroughs.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Public
- Headquarters
- Salt Lake City, United States
- Region
- North America
- Founded
- 2013
- Total funding
- $665M raised
Notable investors: Mubadala Investment Company, Baillie Gifford, Lux Capital, Two Sigma Ventures.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
Closing the Assay Loop: Inside Anthropic's $400M Wet Lab Pivot
Dr. Dereck Mush, MD, MBA